Danish insulin giant Novo Nordisk's diabetes drug liraglutide has demonstrated strong results in the LEAD-4 trial published in the journal Diabetes Care.
The 26-week, double-blind, placebo-controlled, parallel-group trial randomized 533 subjects with type 2 diabetes to once-daily liraglutide 1.2mg, liraglutide 1.8mg, or placebo in combination with metformin and rosiglitazone.
Mean HbA1c values decreased significantly more in the liraglutide groups versus placebo (-1.5
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze